Factor Xa inhibitors in the prevention of cancer-related venous thromboembolism: lessons learned by clinical trials

References

• 1. Chee CE, Ashrani AA, Marks RS et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 123, 3972–3978 (2014).
  Medline CASGoogle Scholar
• 2. Faller N, Limacher A, Mean M et al. Predictors and causes of long-term mortality in elderly patients with acute venous thromboembolism: a prospective cohort study. Am. J. Med. 130, 198–206 (2017).
  MedlineGoogle Scholar
• 3. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J. Thromb. Haemost. 5(4), 692–699 (2007).
  Medline CASGoogle Scholar
• 4. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J. Am. Coll. Cardiol. 73(11), 1336–1349 (2019).
  Medline CASGoogle Scholar
• 5. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4, 465–473 (2002).
  Medline CASGoogle Scholar
• 6. Lee AYY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146–153 (2003).
  Medline CASGoogle Scholar
• 7. Lee AYY, Kamphuisen PW, Meyer G et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7), 677–686 (2015).
  Medline CASGoogle Scholar
• 8. Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N. Engl. J. Med. 378, 615–624 (2018).
  Medline CASGoogle Scholar
• 9. Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J. Clin. Oncol. 36, 2017–2023 (2018).
  Medline CASGoogle Scholar
• 10. Farge D, Frere C, Connors JM et al. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 20(10), e566–e581 (2019).
  MedlineGoogle Scholar
• 11. Key NS, Khorana AA, Kuderer NM et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 38, 496–520 (2020).
  MedlineGoogle Scholar
• 12. Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N. Engl. J. Med. 382(17), 1599–1607 (2020).
  Medline CASGoogle Scholar
• 13. McBane RD II, Wysokinski WE, Le-Rademacher JG et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J. Thromb. Haemost. 18, 411–421 (2020).
  Medline CASGoogle Scholar
• 14. Giustozzi M, Agnelli G, Del Toro-Cervera J et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb. Haemost. 120(7), 1128–1136 (2020).
  MedlineGoogle Scholar
• 15. Marshall A, Levine M, Hill C et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). J. Thromb. Haemost. 18(4), 905–915 (2020).
  Medline CASGoogle Scholar